PROGNOSTIC SIGNIFICANCE OF STRUMAL CALLA EXPRESSION IN PRIMARY BREAST CARCINOMA IN RELATION TO PATHOLOGICAL RSPONCE AFTER NEOADJUVANT CHEMOTHERAPY
DOI:
https://doi.org/10.63939/v20ary90Keywords:
CALLA immunohistochemistry, CD-10, breast carcinoma, prognostic factor, neoadjuvant chemotherapy, molecular profileAbstract
Background: In this study we aimed to assess the IHC expression of stromal CALLA in invasive breast carcinomas as prognostic factor and correlate its relationship with six clinico-pathological parametrs by assessing the pathological response to neoadjuvant chemotherapy
Method: Study design is cross-sectional, it conducted on 50 females with breast invasive ductal carcinoma, FFPE tissue blocks collected from the archive of laboratory of Al-Sader medical city - Al Najaf governorate/ Iraq, during the period from September 2023 to September 2024. CALLA immunohistochemistry expression detected by labeled polymers and enhanced polymer system (Dako En-Vision™ Flex) Dako-protocol. it was correlated with age of patients, tumor grade, hormonal expression, her-2/neo expression, Ki-67 expression and molecular profile.
Result: Stromal CALLA immunohistochemistry was expressed in 48%. There is statistically significant positive correlations between stromal expression and response to neoadjuvant chemotherapy (P = 0.011), most cases with positive CALLA expression either nonresponding to NAC or achieved partial response while most of CALLA negative cases achieved complete pathological response the same for her-2 positive cases, though statistically non-significant but most CALLA expressed cases were Grade III, her-2 enriched and triple negative molecular profile most of them had partial pathological response (not complete)
Conclusions: Stromal CALLA had been expressed in 48% of invasive ductal carcinoma and there is positive correlation between stromal CALLA expressions and higher tumor grades, her-2 expression and triple negative profile suggesting the effects of stromal CALLA expression on aggressive behavior of breast ductal carcinoma with decreasing a chance of complete pathological response after neoadjuvant chemotherapy
Downloads
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3):209-49.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
3. Yuan JQ, Wang SM, Tang LL, Mao J, Wu YH, Hai J, et al. Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy. Breast cancer research and treatment. 2015;151(2):405-13.
4. Abdel-Rahman O. Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast cancer research and treatment. 2018;168(1):269-75.
5. Arneth B. Tumor microenvironment. Medicina. 2019;56(1):15.
6. H. H. Nienhuis SBMG, H. Timmer-Bosscha et al. “Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets,”. Pharmacology & Therapeutics. 2015;147:63-79.
7. Sjöberg E, Augsten M, Bergh J, Jirström K, Östman A. Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. British Journal of Cancer. 2016;114(10):1117-24.
8. Eiró N, Fernandez-Garcia B, Vázquez J, Del Casar JM, González LO, Vizoso FJ. A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer. Oncoimmunology. 2015;4(7):e992222.
9. Sadaka E, Almorsy W, Elsaka A. CD10 expression as a prognostic factor in female patients with invasive ductal carcinoma of the breast. J Am Sci. 2016;12(4):71-7.
10. Oba J, Nakahara T, Hashimoto-Hachiya A, Liu M, Abe T, Hagihara A, et al. CD10-equipped melanoma cells acquire highly potent tumorigenic activity: A plausible explanation of their significance for a poor prognosis. PloS one. 2016;11(2):e0149285.
11. Zhu Y, Zheng JJ, Yang F, Nie QQ, Zhu ZL, Deng H. Expression of CD10 in cancer-associated fibroblasts and its effect on initiation and progression of colorectal carcinoma. Zhonghua Bing li xue za zhi= Chinese Journal of Pathology. 2016;45(12):859-65.
12. Gourzones C, Barjon C, Busson P. Host–tumor interactions in nasopharyngeal carcinomas. Seminars in cancer biology. 2012;22(2):127-36.
13. Mishra D, Singh S, Narayan G. Role of B cell development marker CD10 in cancer progression and prognosis. Molecular biology international. 2016;2016.
14. Hilton HN, Santucci N, Silvestri A, Kantimm S, Huschtscha LI, Graham JD, et al. Progesterone stimulates progenitor cells in normal human breast and breast cancer cells. Breast cancer research and treatment. 2014;143(3):423-33.
15. Hashim MJ, Al-Shamsi FA, Al-Marzooqi NA, Al-Qasemi SS, Mokdad AH, Khan G. Burden of Breast Cancer in the Arab World: Findings from Global Burden of Disease, 2016. Journal of epidemiology and global health. 2018;8(1-2):54-8.
16. Li H, Yuan SL, Han ZZ, Huang J, Cui L, Jiang CQ, et al. Prognostic significance of the tumor-stroma ratio in gallbladder cancer. Neoplasma. 2017;64(4):588-93.
17. Dhande AN, Sinai Khandeparkar SG, Joshi AR, Kulkarni MM, Pandya N, Mohanapure N, et al. Stromal expression of CD10 in breast carcinoma and its correlation with clinicopathological parameters. South Asian J Cancer. 2019;8(1):18-21.
18. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA Cancer J Clin. 2022;72(6):524-41.
19. Hashim HT, Ramadhan MA, Theban KM, Bchara J, El-Abed-El-Rassoul A, Shah J. Assessment of breast cancer risk among Iraqi women in 2019. BMC Women's Health. 2021;21(1):412.
20. Alwan NA. Breast cancer: demographic characteristics and clinico-pathological presentation of patients in Iraq. East Mediterr Health J. 2010;16(11):1159-64.
21. Abdulkareem AA, Ghalib HA, Rashaan MI. Factors causing delayed presentations of breast cancer among female patients in Sulaimani Governorate, Kurdistan region, Iraq. BMC Womens Health. 2023;23(1):612.
22. World Health O. Revised global burden of disease (GBD) 2002 estimates, 2005. Availa-ble from: http://www who int/healthinfo/global_burden_disease/en/index html[accessed on 2016 Dec 20]. 2009.
23. Freedman LS, Edwards BK, Ries LAG, Young JL. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER. 2006.
24. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians. 2022;72(6):524-41.
25. Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, et al. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer. 2021;124(2):315-32.
26. Al-Bedairy IH, AlFaisal AHM, Al-Gazali HR, Al H. Molecular Subtypes by Immunohistochemical for Iraqi Women with Breast Cancer. Iraqi journal of biotechnology. 2020;19(1).
27. Alwan NAS, Tawfeeq FN, Muallah FH. Breast cancer subtypes among Iraqi patients: identified by their Er, Pr and Her2 Status. Journal of the Faculty of Medicine Baghdad. 2017;59(4):303-7.
28. Al-Rawaq KJ, Al-Naqqash MA, Jassim MK. Molecular classification of Iraqi breast cancer patients and its correlation with patients’ profile. Journal of the Faculty of Medicine Baghdad. 2016;58(3):197-201.
29. Olah O, Majlat E, Koszo R, Vereb Z, Voros A. Predictive role of neostromal CD10 expression in breast cancer patients treated with neoadjuvant chemotherapy. Pathol Oncol Res. 2022;28:1610598.
30. Louhichi T, Saad H, Dhiab MB, Ziadi S, Trimeche M. Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype. BMC cancer. 2018;18:1-9.
31. Makni S, Mellouli M, Saguem I, Boudawara O, Gouiaa N, Boudawara TS, et al. The Prognostic Significance of CD10 Expression in Invasive Breast Carcinoma in Tunisian Patients. The Gulf Journal of Oncology. 2022;1(40):15-23.
32. A.K. Boler, S. Akhtar, A. Bandyopadhyay, G. Bandyopadhyay. A study of CD10 positivity of stromal cells in core needle biopsy specimen of breast cancer patients and its relation with histological grade and lymphovascular invasion Indian J. Pathol. Microbiol., 64 (3) (2021), pp. 460-463 Jul-Sep. (PubMed PMID: 34341253)
33. Puri V, Jain M, Thomas S. Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67. Int J Bre Can 2011; 2011:1-4.
34. Diem Thi-Ngoc Vom, et al.Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma DOI: 10.1007/s12282-013-0459-1 April 2013 Breast Cancer 22(2)
35. Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotypeLouhichi T, Saad H, Dhiab MB , Ziadi S, Trimeche M. BMC cancer.2018;18(1). CrossRef
36. Hagenaars SC, de Groot S, Cohen D, Dekker TJA, Charehbili A, Meershoek-Klein Kranenbarg E, et al. Tumor-stroma ratio is associated with Miller-Payne score and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer. International Journal of Cancer. 2021;149(5):1181-8.
37. Jana SH, Jha BM, Patel C, Jana D, Agarwal A. CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. Ind J Pathol Microbio 2014; 57:530-6.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
